Medical spray protection sterile liquid and preparation process thereof

Abstract

The invention relates to a medical spray protection sterile liquid and a preparation process thereof, and relates to the field of medical liquids and preparation, and the medical spray protection sterile liquid is prepared from the following raw materials in percentage by mass: 1-1.4% of modified alginate, 0.3-0.5% of trehalose, 1.2-1.4% of alginate oligosaccharide, 0.5-0.9% of sodium chloride and the balance of a PBS buffer solution. The preparation method comprises the following steps: adding modified alginate, trehalose, alginate oligosaccharide and sodium chloride into a PBS (Phosphate Buffer Solution), stirring in a dark place until the materials are completely dissolved, filtering and sub-packaging to obtain the medical spray protection sterile liquid. The medical spray protection sterile liquid prepared by the invention can meet the requirements in multiple aspects of preventing infection, promoting wound healing, relieving respiratory tract discomfort and the like.

Description

TECHNICAL FIELD

[0001] The present application relates to the field of medical liquids and preparation, in particular to a medical spouting protective sterile liquid and a preparation process thereof. BACKGROUND

[0002] In the medical field, the nursing and disease prevention of human oral cavity, respiratory tract and other parts have always been the focus. With the improvement of people's health consciousness and the improvement of the requirement for medical quality, the demand for medical protective products is also increasing. As a common medical product, the medical spouting protective sterile liquid plays an important role in preventing infection, promoting wound healing and relieving respiratory discomfort, and its research and improvement have positive significance for improving medical care level and protecting people's health.

[0003] To solve the problem of oral cavity and respiratory tract nursing and protection, there are many conventional means. Some traditional methods are to use ordinary mouthwash, which is usually mixed with simple disinfecting ingredients and spices, mainly for cleaning the oral cavity and removing odor. Some others are to use ordinary spray preparations, which contain some antibacterial drugs, and act on the surface of oral cavity and respiratory tract through spraying to achieve the purpose of antibiosis and symptom relief. In addition, some use physiological saline for spouting, which uses its cleaning and moisturizing effect to relieve respiratory discomfort. However, the existing medical spouting protective sterile liquid has poor protection and nursing effect, and cannot well meet the needs of preventing infection, promoting wound healing and relieving respiratory discomfort, so it needs to be improved. SUMMARY

[0004] In order to improve the performance of the medical spouting protective sterile liquid, the present application provides a medical spouting protective sterile liquid and a preparation process thereof.

[0005] The medical spouting protective sterile liquid and the preparation process thereof provided by the present application adopt the following technical solutions: In the first aspect, the present application provides a medical spouting protective sterile liquid, which adopts the following technical solutions: A medical spouting protective sterile liquid, the preparation raw materials include the following mass percentage components: Modified alginate 1-1.4% Trehalose 0.3-0.5% Alginate oligosaccharide 1.2-1.4% Sodium chloride 0.5-0.9% PBS buffer solution in residual amount; The modified alginate is prepared by the following steps: The sodium alginate is added to a solvent, a ferric chloride solution is added, and a coordination gel is obtained after stirring. The coordination gel is broken, immersed in an oleuropein solution, and shaken in the dark. After centrifugation, washing, and drying, a modified alginate is obtained.

[0006] The gel structure formed by the coordination of sodium alginate and iron ions is modified by oleuropein, which not only enhances the stability and adhesion of the material to form a physical barrier, but also introduces the antioxidant and soothing properties of oleuropein, cooperates with the local microenvironment regulation of iron ions, and helps to maintain the local microenvironment. The addition of trehalose mainly provides moisturizing and cell protection functions to protect the integrity of the oral and throat mucosa. Brown alginate has good biocompatibility and biological activity, which can assist in regulating the local immune response and supporting tissue repair. Sodium chloride regulates the osmotic pressure, and the PBS buffer ensures the stability of the system pH, reducing the irritation to sensitive tissues. The above components cooperate and synergize to form a mild protective layer in the oral cavity, throat, and other parts, and through physical barrier, moisturizing and nourishing, anti-inflammatory activity, and tissue support, they meet the multiple needs of preventing local infection, assisting wound repair, and relieving discomfort caused by respiratory mucosa dryness or irritation.

[0007] Preferably, the molar ratio of sodium alginate to oleuropein is 1:(0.25-0.35).

[0008] The modified alginate prepared according to the above molar ratio can effectively improve the performance of sterile liquid in preventing infection, promoting wound healing, and relieving respiratory discomfort.

[0009] Preferably, the preparation of the modified alginate also includes ε-polylysine, and the preparation is carried out by the following steps: adding sodium alginate to a solvent, adding a ferric chloride solution, stirring to obtain a coordination gel, breaking the coordination gel, immersing it in a mixed solution containing oleuropein and ε-polylysine, shaking in the dark, and then centrifuging, washing, and drying to obtain the modified alginate.

[0010] ε-polylysine is embedded in the gel structure due to its cationic properties, which not only enhances the intervention ability of the microbial cell membrane through charge interaction and directly supplements the antibacterial activity, but also stabilizes the gel network together with oleuropein and regulates the local microenvironment. The synergistic effect of the three not only strengthens the stability and functional continuity of the physical barrier, but also improves the comprehensive protection effect of the sterile liquid in the oral and throat areas through the multi-path linkage of antibacterial-antioxidant-microenvironment regulation, which covers the needs of infection risk prevention and control, supports tissue repair, and relieves discomfort caused by mucosa irritation.

[0011] Preferably, the molar ratio of sodium alginate to ε-polylysine is 1:(0.04-0.06).

[0012] The modified alginate prepared according to the above molar ratio can further improve the performance of sterile solutions in preventing infection, promoting wound healing, and relieving respiratory discomfort.

[0013] Preferably, the raw materials used in the preparation also include panthenol.

[0014] Trehalose provides a basic protective barrier for mucous membranes by stabilizing cell membrane structure and protein activity; panthenol, on the other hand, is converted into an active form that penetrates deep into tissues, promoting epithelial cell metabolism and migration. The synergy between the two not only prolongs the moist state of the mucous membranes but also optimizes the wound microenvironment through complementary cell protection mechanisms, with trehalose's stress resistance and panthenol's restorative properties. The combination of the two can also further synergize with other components of the gargle spray, relying on the physical support of the modified alginate gel network to continuously release moisturizing factors. Together with the antioxidant activity of oleuropein, it reduces oxidative damage, while also synergizing with the immunomodulatory effects of fucoidan. On the basis of maintaining mucous membrane integrity, the panthenol-trehalose system amplifies tissue repair efficacy and enhances respiratory comfort by relieving dryness and irritation. This results in a more balanced physiological-level synergistic intervention in infection control, wound healing, and discomfort relief.

[0015] Preferably, the molar ratio of panthenol to trehalose is (0.3-0.5):1.

[0016] The combination of panthenol and trehalose in the above molar ratio can more effectively improve the performance of medical spray-on protective sterile solution in terms of infection control, wound healing and discomfort relief.

[0017] Preferably, the raw materials used in the preparation also include a zinc glutathione complex.

[0018] The zinc ions in the glutathione zinc complex replenish and enhance the passive antibacterial defense of the modified alginate gel network by disrupting the integrity of the microbial membrane. Meanwhile, the glutathione component and oleuropein work together to scavenge reactive oxygen species, forming a superimposed antioxidant protective layer to reduce mucosal oxidative damage. The zinc ions in the glutathione zinc complex, in conjunction with the immunomodulatory effects of fucoidan oligosaccharides, optimize the wound microenvironment by supporting the expression of epithelial repair genes. The addition of the glutathione zinc complex, while maintaining the mildness of the system, upgrades the basic protective layer into a dynamic defense system with physical barrier, active antibacterial intervention, and synergistic antioxidant capabilities, jointly supporting infection risk control and alleviating oxidative stress-related discomfort.

[0019] Preferably, the glutathione zinc complex is prepared using the following steps: Glutathione was added to a solvent, heated and then cooled, and stirred to obtain a glutathione solution. Under neutral gas protection, zinc chloride solution was added to the glutathione solution, the pH was adjusted to acidic, stirred in the dark, precipitated with alcohol, washed, and dried to obtain a glutathione-zinc complex.

[0020] Preferably, the amount of the glutathione zinc complex added is 0.05-0.15%.

[0021] The glutathione zinc complex prepared and added according to the above method can effectively improve the performance of medical spray-on protective sterile solution in preventing infection, promoting wound healing and relieving respiratory discomfort.

[0022] Secondly, this application provides a preparation process for a medical spray-on protective sterile solution, which adopts the following technical solution: A preparation process for a medical spray-on protective sterile solution includes the following steps: Modified alginate, trehalose, fucoidan and sodium chloride were added to PBS buffer, stirred in the dark until completely dissolved, filtered and dispensed to obtain a sterile medical spray for protection.

[0023] The medical protective sterile solution prepared according to the above steps is suitable for the care of non-chronic wounds, acting as a physical barrier to promote wound healing; it moistens viscous secretions such as sputum and nasal mucus, moistens the respiratory tract, and relieves dryness, edema and discomfort caused by upper respiratory tract infections; it inhibits the colonization of influenza pathogens, reduces the viral load of influenza, and relieves symptoms such as swelling, pain, nasal congestion, runny nose, cough and wheezing caused by influenza in the upper respiratory system.

[0024] In summary, this application includes at least one of the following beneficial technical effects: 1. The gel structure formed by sodium alginate and iron ions, after modification with oleuropein, not only enhances the stability and adhesion of the material and forms a physical barrier, but also introduces the antioxidant and soothing properties of oleuropein. This, combined with the local microenvironment regulation by iron ions, helps maintain the local microenvironment. The addition of trehalose primarily provides moisturizing and cell protection functions, protecting the integrity of the oral and pharyngeal mucosa. Alginate itself has good biocompatibility and bioactivity, which can help regulate local immune responses and support tissue repair processes. Sodium chloride regulates osmotic pressure, while PBS buffer ensures system pH stability, reducing irritation to sensitive tissues. These components work synergistically to form a gentle protective layer in the oral cavity and pharynx, meeting multiple needs such as preventing local infection, assisting wound repair, and relieving discomfort caused by dryness or irritation of the respiratory mucosa through physical barrier, moisturizing and nourishing, anti-inflammatory activity, and tissue support.

[0025] 2. ε-Polylysine, with its cationic properties, is embedded in the gel structure. On the one hand, it enhances the ability to intervene in microbial cell membranes through charge interaction, directly supplementing antibacterial activity. On the other hand, it works with oleuropein to stabilize the gel network and regulate the local microenvironment. The synergistic effect of the three not only strengthens the stability and functional continuity of the physical barrier, but also enhances the comprehensive protective effect of the sterile gargle in the oral cavity and pharynx through multi-pathway linkage of antibacterial, antioxidant and microenvironment regulation. While maintaining mucosal moisture and physiological balance, it more comprehensively covers the needs of infection risk prevention and control, supporting tissue repair and relieving discomfort caused by mucosal irritation.

[0026] 3. Zinc ions in the glutathione zinc complex replenish and enhance the passive antibacterial defense of the modified alginate gel network by disrupting the integrity of the microbial membrane. Meanwhile, the glutathione component and oleuropein work together to scavenge reactive oxygen species, forming a superimposed antioxidant protective layer to reduce mucosal oxidative damage. The zinc ions in the glutathione zinc complex, in conjunction with the immunomodulatory effects of fucoidan oligosaccharides, optimize the wound microenvironment by supporting the expression of epithelial repair genes. The addition of the glutathione zinc complex, while maintaining the mildness of the system, upgrades the basic protective layer into a dynamic defense system with physical barrier, active antibacterial intervention, and synergistic antioxidant capabilities, jointly supporting infection risk control and alleviating oxidative stress-related discomfort. Detailed Implementation

[0027] This application discloses a medical spray-on protective sterile solution and its preparation process. Unless otherwise specified, all raw materials used in this application are commercially available. The following detailed description, in conjunction with embodiments, further illustrates this application: Raw material specifications: Sodium alginate (CAS No.: 9005-38-3), purchased from Henan Chengqi Food Co., Ltd.; oleuropein (CAS No.: 32619-42-4), purchased from Manster (Chengdu) Biotechnology Co., Ltd.; trehalose (CAS No.: 99-20-7), purchased from Mingrui Group (Henan) Co., Ltd.; fucoidan, purchased from Shandong Pingju Biotechnology Co., Ltd.; PBS buffer H17536-2L, purchased from Wanjia Standard Materials; ε-polylysine GC14479, purchased from Shanghai Guchen Biotechnology Co., Ltd.; citrate buffer R26094, purchased from Shanghai Yuanye Biotechnology Co., Ltd.; EDTA (CAS No.: 60-00-4); panthenol DL-panthenol (CAS No.: 16485-10-2), purchased from Wuhan Chengtian Fine Chemical Co., Ltd.; glutathione, purchased from Hefei Shengrun Biological Products Co., Ltd.

[0028] Example 1 Preparation of modified alginate The molar ratio of sodium alginate to oleuropein is 1:0.25.

[0029] Sodium alginate was added to deionized water (concentration 2%), followed by ferric chloride aqueous solution. The molar ratio of sodium alginate carboxyl groups to ferric chloride was 3:1. The mixture was stirred at 200 rpm for 30 min at 25 °C to obtain a coordination gel. The coordination gel was broken down to a particle size of less than 100 μm and immersed in an oleuropein solution (pH 5, ethanol to water volume ratio 1:19, solid content 10%). The mixture was shaken in the dark at 25 °C for 4 h, centrifuged, and washed three times each with citrate buffer (pH 6.5) and 0.1 mmol / L EDTA aqueous solution. The mixture was then freeze-dried at -50 °C to obtain modified alginate.

[0030] Preparation of medical spray protective sterile solution Percentage of each component: modified alginate 1%, trehalose 0.3%, fucoidan 1.2%, sodium chloride 0.5%, PBS buffer to 100%.

[0031] Modified alginate, trehalose, fucoidan and sodium chloride were sequentially dissolved in PBS buffer at pH 6.5. The solution was stirred at 200 rpm at 25°C in the dark until completely dissolved. The solution was then filtered through a 0.22 μm sterile filter membrane and dispensed to obtain a sterile medical spray for protection.

[0032] Example 2 Preparation of modified alginate The molar ratio of sodium alginate to oleuropein is 1:0.35.

[0033] Sodium alginate was added to deionized water (concentration 2%), followed by ferric chloride aqueous solution. The molar ratio of sodium alginate carboxyl groups to ferric chloride was 3:1. The mixture was stirred at 200 rpm for 30 min at 25 °C to obtain a coordination gel. The coordination gel was broken down to a particle size of less than 100 μm and immersed in an oleuropein solution (pH 5, ethanol to water volume ratio 1:19, solid content 10%). The mixture was shaken in the dark at 25 °C for 4 h, centrifuged, and washed three times each with citrate buffer (pH 6.5) and 0.1 mmol / L EDTA aqueous solution. The mixture was then freeze-dried at -50 °C to obtain modified alginate.

[0034] Preparation of medical spray protective sterile solution Percentage of each component: modified alginate 1.4%, trehalose 0.5%, fucoidan 1.4%, sodium chloride 0.9%, PBS buffer to 100%.

[0035] Modified alginate, trehalose, fucoidan and sodium chloride were sequentially dissolved in PBS buffer at pH 6.5. The solution was stirred at 200 rpm at 25°C in the dark until completely dissolved. The solution was then filtered through a 0.22 μm sterile filter membrane and dispensed to obtain a sterile medical spray for protection.

[0036] Example 3 Preparation of modified alginate The molar ratio of sodium alginate to oleuropein is 1:0.3.

[0037] Sodium alginate was added to deionized water (concentration 2%), followed by ferric chloride aqueous solution. The molar ratio of sodium alginate carboxyl groups to ferric chloride was 3:1. The mixture was stirred at 200 rpm for 30 min at 25 °C to obtain a coordination gel. The coordination gel was broken down to a particle size of less than 100 μm and immersed in an oleuropein solution (pH 5, ethanol to water volume ratio 1:19, solid content 10%). The mixture was shaken in the dark at 25 °C for 4 h, centrifuged, and washed three times each with citrate buffer (pH 6.5) and 0.1 mmol / L EDTA aqueous solution. The mixture was then freeze-dried at -50 °C to obtain modified alginate.

[0038] Preparation of medical spray protective sterile solution Percentage of each component: modified alginate 1.2%, trehalose 0.4%, fucoidan 1.3%, sodium chloride 0.7%, PBS buffer to 100%.

[0039] Modified alginate, trehalose, fucoidan and sodium chloride were sequentially dissolved in PBS buffer at pH 6.5. The solution was stirred at 200 rpm at 25°C in the dark until completely dissolved. The solution was then filtered through a 0.22 μm sterile filter membrane and dispensed to obtain a sterile medical spray for protection.

[0040] Example 4 Example 4 is based on Example 3. The only difference between Example 4 and Example 3 is that the molar ratio of sodium alginate and oleuropein in Example 4 is 1:0.15.

[0041] Example 5 Example 5 is based on Example 3. The only difference between Example 5 and Example 3 is that the molar ratio of sodium alginate and oleuropein in Example 5 is 1:0.5.

[0042] Example 6 Example 6 is based on Example 3. The only difference between Example 6 and Example 3 is that the raw material for preparing the modified alginate in Example 6 also includes ε-polylysine, and it is prepared using the following steps: The molar ratio of sodium alginate to oleuropein is 1:0.3, and the molar ratio of sodium alginate to ε-polylysine is 1:0.04.

[0043] Sodium alginate was added to deionized water (concentration 2%), followed by ferric chloride aqueous solution. The mixture was stirred at 200 rpm for 30 min at 25 °C to obtain a coordination gel. The coordination gel was broken down to a particle size of less than 100 μm and immersed in a mixed solution containing oleuropein and ε-polylysine (pH 5, ethanol to water volume ratio 1:19, solid content 10%). The mixture was shaken in the dark at 25 °C for 4 h, centrifuged, and washed three times each with citrate buffer (pH 6.5) and 0.1 mmol / L EDTA aqueous solution. The mixture was then freeze-dried at -50 °C to obtain modified alginate.

[0044] Example 7 Example 7 is based on Example 3. The only difference between Example 7 and Example 3 is that the molar ratio of sodium alginate to ε-polylysine in Example 7 is 1:0.06.

[0045] Example 8 Example 8 is based on Example 3. The only difference between Example 8 and Example 3 is that the molar ratio of sodium alginate and ε-polylysine in Example 8 is 1:0.05.

[0046] Example 9 Example 9 is based on Example 3. The only difference between Example 9 and Example 3 is that the molar ratio of sodium alginate to ε-polylysine in Example 9 is 1:0.02.

[0047] Example 10 Example 10 is based on Example 3. The only difference between Example 10 and Example 3 is that the molar ratio of sodium alginate to ε-polylysine in Example 10 is 1:0.08.

[0048] Example 11 Example 11 is based on Example 3. The only difference between Example 11 and Example 3 is that in Example 11, oleuropein is not added to the modified alginate, but only ε-polylysine is added.

[0049] The molar ratio of sodium alginate to ε-polylysine is 1:0.05.

[0050] Sodium alginate was added to deionized water (concentration 2%), followed by ferric chloride aqueous solution. The mixture was stirred at 200 rpm for 30 min at 25 °C to obtain a coordination gel. The coordination gel was broken down to a particle size of less than 100 μm and immersed in ε-polylysine aqueous solution (pH 5, solid content 10%). The mixture was shaken in the dark at 25 °C for 4 h, centrifuged, and washed three times each with citrate buffer (pH 6.5) and 0.1 mmol / L EDTA aqueous solution. The mixture was then freeze-dried at -50 °C to obtain modified alginate.

[0051] Example 12 Example 12 is based on Example 3. The only difference between Example 12 and Example 3 is that the raw materials used in Example 12 also include panthenol, and the molar ratio of panthenol to trehalose is 0.3:1.

[0052] Preparation of medical spray protective sterile solution The molar ratio of panthenol to trehalose was 0.3:1; the percentages of each component were as follows: modified alginate 1.2%, trehalose 0.4%, fucoidan 1.3%, sodium chloride 0.7%, panthenol 0.12%, and PBS buffer was added to bring the total to 100%.

[0053] Modified alginate, trehalose, panthenol, fucoidan and sodium chloride were sequentially dissolved in PBS buffer at pH 6.5. The solution was stirred at 200 rpm at 25°C in the dark until completely dissolved. The solution was then filtered through a 0.22 μm sterile filter membrane and dispensed to obtain a sterile medical spray for protection.

[0054] Example 13 Example 13 is based on Example 12. The only difference between Example 13 and Example 12 is that the molar ratio of panthenol to trehalose in Example 13 is 0.5:1.

[0055] Example 14 Example 14 is based on Example 12. The only difference between Example 14 and Example 12 is that the molar ratio of panthenol to trehalose in Example 14 is 0.4:1.

[0056] Example 15 Example 15 is based on Example 12. The only difference between Example 15 and Example 12 is that the molar ratio of panthenol to trehalose in Example 15 is 0.2:1.

[0057] Example 16 Example 16 is based on Example 12. The only difference between Example 16 and Example 12 is that the molar ratio of panthenol to trehalose in Example 16 is 0.6:1.

[0058] Example 17 Example 17 is based on Example 3. The only difference between Example 17 and Example 3 is that in Example 17, trehalose is replaced with an equal amount of panthenol.

[0059] Example 18 Example 18 is based on Example 3. The only difference between Example 18 and Example 3 is that the raw materials used in Example 18 also include 0.05% of glutathione zinc complex.

[0060] Preparation of glutathione zinc complex Glutathione was added to deionized water, heated to boiling, and then cooled to 4°C. The mixture was stirred at 200 rpm for 20 min to obtain a glutathione solution (concentration 10%). Under nitrogen protection, a zinc chloride aqueous solution (concentration 5%) was added to the glutathione solution, with a glutathione to zinc ion molar ratio of 2:1. The pH was adjusted to 6.0 using 0.1 mol / L hydrochloric acid. The mixture was stirred at 200 rpm for 3 h at 25°C in the dark. Precipitation was carried out with anhydrous ethanol, centrifuged, washed with anhydrous ethanol, and freeze-dried at -20°C to obtain the glutathione-zinc complex.

[0061] Preparation of medical spray protective sterile solution Percentage of each component: modified alginate 1.2%, trehalose 0.4%, fucoidan 1.3%, sodium chloride 0.7%, glutathione zinc complex 0.05%, PBS buffer to 100%.

[0062] Modified alginate, trehalose, fucoidan and sodium chloride were sequentially dissolved in PBS buffer at pH 6.5. Glutathione zinc complex was added, and the solution was stirred at 200 rpm at 25°C in the dark until completely dissolved. The solution was then filtered through a 0.22 μm sterile filter membrane and dispensed to obtain a sterile medical spray for protection.

[0063] Example 19 Example 19 is based on Example 3. The only difference between Example 19 and Example 3 is that the amount of glutathione zinc complex added in Example 19 is 0.15%.

[0064] Example 20 Example 20 is based on Example 3. The only difference between Example 20 and Example 3 is that the amount of glutathione zinc complex added in Example 20 is 0.1%.

[0065] Example 21 Example 21 is based on Example 3. The only difference between Example 21 and Example 3 is that the amount of glutathione zinc complex added in Example 21 is 0.02%.

[0066] Example 22 Example 22 is based on Example 3. The only difference between Example 22 and Example 3 is that the amount of glutathione zinc complex added in Example 22 is 0.2%.

[0067] Comparative Example 1 Comparative Example 1 is based on Example 3. The only difference between Comparative Example 1 and Example 3 is that the modified alginate is replaced with sodium alginate in Comparative Example 1.

[0068] Preparation of medical spray protective sterile solution Percentage of each component: sodium alginate 1.2%, trehalose 0.4%, fucoidan 1.3%, sodium chloride 0.7%, PBS buffer to 100%.

[0069] Sodium alginate, trehalose, fucoidan and sodium chloride were dissolved sequentially in PBS buffer at pH 6.5. The solution was stirred at 200 rpm at 25°C in the dark until completely dissolved. The solution was then filtered through a 0.22 μm sterile filter membrane and dispensed to obtain a sterile medical spray for protection.

[0070] Performance testing (1) The standard of "WS / T 650-2019 Evaluation Method for Antibacterial and Bacteriostatic Effects" was selected. The antibacterial rate of the sample against Escherichia coli, Staphylococcus aureus and Candida albicans was tested by shaking flask method. Each sample was tested three times, and the average value was taken after measurement. The results are recorded in Table 1.

[0071] (2) The standard GB / T 39498-2020 General Rules for Cytokine Detection was selected. Human gingival fibroblasts were used. The inflammatory state was induced by LPS (1 μg / mL). The sample was added and cultured for 24 h. The supernatant was collected for quantitative analysis of IL-6 and TNF-α content. The downregulation amount was calculated. Each sample was tested three times. The average value was taken after measurement. The results are recorded in Table 1.

[0072] Table 1. Test results of antibacterial and anti-inflammatory properties of medical spray-on protective sterile solution. As shown in Table 1, the antibacterial rate of Escherichia coli in Examples 1-3 is greater than 85.4%, the antibacterial rate of Staphylococcus aureus is greater than 87.8%, the antibacterial rate of Candida albicans is greater than 80.1%, the downregulation of IL-6 is greater than 45.2%, and the downregulation of TNF-α is greater than 40.5%. This demonstrates that the medical spray-gargling protective sterile solution prepared in this application has good performance in preventing infection, promoting wound healing, and relieving respiratory discomfort.

[0073] As shown in Table 1, the only difference between Examples 4 and 5 and Example 3 is that the synthesis ratio of modified alginate was disrupted in Examples 4 and 5. Compared with Example 3, the performance of Examples 4 and 5 decreased. This is because too little oleuropein has limited performance, while too much will affect the stability of the gel network, thus reducing the performance of both.

[0074] As shown in Table 1, the difference between Examples 6-11 and Example 3 is only that: in Examples 6-8, ε-polylysine with a limited ratio was used for further modification treatment, and the performance was further improved through the synergistic effect between the components; in Examples 9 and 10, the limited ratio was destroyed, and the performance improvement effect was reduced; in Example 11, no oleuropein was added, only ε-polylysine was added, the synergistic effect was affected, and the performance was significantly reduced.

[0075] As shown in Table 1, the only difference between Examples 12-17 and Example 3 is that: in Examples 12-14, a specific ratio of panthenol was added, and the performance improved through the synergistic effect with trehalose; in Examples 15 and 16, the specific ratio was disrupted, and the performance improvement effect was slightly reduced; in Example 17, panthenol was used to replace trehalose, and the multiple synergistic effects of trehalose were lacking, resulting in a significant decrease in performance.

[0076] As shown in Table 1, the only difference between Examples 18-22 and Example 3 is that: in Examples 18-20, a glutathione zinc complex with a limited ratio range was added, which significantly improved the performance by enhancing the synergistic effect between the components in the medical spray protective sterile solution; in Examples 21 and 22, the limited ratio was disrupted, and the performance improvement effect was slightly reduced.

[0077] As shown in Table 1, the only difference between Comparative Example 1 and Example 3 is that the modified alginate was replaced with sodium alginate in Comparative Example 1, which lacked the introduction of oleuropein and iron cross-linking structure, resulting in a decrease in the synergistic effect between components and a significant decrease in the performance of the medical spray protective sterile solution.

[0078] This specific embodiment is merely an explanation of this application and is not intended to limit it. Based on the above description, those skilled in the art can make various changes and modifications without departing from the technical concept of this application. The technical scope of this application is not limited to the contents of the specification but must be determined according to the scope of the claims.

Claims

1. A medical spray-on protective sterile solution, characterized in that: The raw materials for preparation include the following components in weight percentage: Modified alginate 1-1.4% Trehalose 0.3-0.5% Fucoidan 1.2-1.4% Sodium chloride 0.5-0.9% Remaining PBS buffer; The modified alginate was prepared using the following steps: Sodium alginate was added to a solvent, followed by ferric chloride solution. After stirring, a coordination gel was obtained. The coordination gel was broken up, immersed in oleuropein solution, shaken in the dark, centrifuged, washed, and dried to obtain modified alginate.

2. The medical spray-on protective sterile solution according to claim 1, characterized in that: The molar ratio of sodium alginate to oleuropein is 1:(0.25-0.35).

3. The medical spray-on protective sterile solution according to claim 2, characterized in that: The modified alginate is prepared from ε-polylysine using the following steps: Sodium alginate was added to a solvent, followed by ferric chloride solution. After stirring, a coordination gel was obtained. The coordination gel was broken up and immersed in a mixed solution containing oleuropein and ε-polylysine. After shaking in the dark, the mixture was centrifuged, washed, and dried to obtain modified alginate.

4. The medical spray-on protective sterile solution according to claim 3, characterized in that: The molar ratio of sodium alginate to ε-polylysine is 1:(0.04-0.06).

5. The medical spray-on protective sterile solution according to claim 1, characterized in that: The raw materials used in the preparation also include panthenol.

6. The medical spray-on protective sterile solution according to claim 5, characterized in that: The molar ratio of panthenol to trehalose is (0.3-0.5):

1.

7. The medical spray-on protective sterile solution according to claim 1, characterized in that: The raw materials used in the preparation also include a zinc glutathione complex.

8. The medical spray-on protective sterile solution according to claim 7, characterized in that: The glutathione zinc complex was prepared using the following steps: Glutathione was added to a solvent, heated and then cooled, and stirred to obtain a glutathione solution. Under neutral gas protection, zinc chloride solution was added to the glutathione solution, the pH was adjusted to acidic, stirred in the dark, precipitated with alcohol, washed, and dried to obtain a glutathione-zinc complex.

9. A medical spray-on protective sterile solution according to claim 8, characterized in that: The amount of the glutathione zinc complex added is 0.05-0.15%.

10. A preparation process for a medical spray-on protective sterile solution as described in any one of claims 1-9, characterized in that: Includes the following steps: Modified alginate, trehalose, fucoidan and sodium chloride were added to PBS buffer, stirred in the dark until completely dissolved, filtered and dispensed to obtain a sterile medical spray for protection.

Images